These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23717383)

  • 21. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.
    Nguyen Y; Nocturne G; Henry J; Ng WF; Belkhir R; Desmoulins F; Bergé E; Morel J; Perdriger A; Dernis E; Devauchelle-Pensec V; Sène D; Dieudé P; Couderc M; Fauchais AL; Larroche C; Vittecoq O; Salliot C; Hachulla E; Le Guern V; Gottenberg JE; Mariette X; Seror R
    Lancet Rheumatol; 2024 Apr; 6(4):e216-e225. PubMed ID: 38437852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome.
    Mumcu G; Biçakçigil M; Yilmaz N; Ozay H; Karaçayli U; Cimilli H; Yavuz S
    Oral Health Prev Dent; 2013; 11(3):229-34. PubMed ID: 23878841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
    Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
    Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperviscosity in primary Sjögren's syndrome: clinical implications.
    Hernández-Molina G; Bermúdez-Bermejo P
    Int J Rheum Dis; 2017 Jan; 20(1):84-89. PubMed ID: 26807556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and salivary neopterin and interferon-gamma in primary Sjögren's syndrome. Correlation with clinical, laboratory and histopathologic features.
    Sfriso P; Ostuni P; Botsios C; Andretta M; Oliviero F; Punzi L; Todesco S
    Scand J Rheumatol; 2003; 32(2):74-8. PubMed ID: 12737324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
    Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
    Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elastographic ultrasound: an additional image tool in Sjögren's syndrome.
    Kimura-Hayama E; Criales-Vera S; Azpeitia-Espinosa L; Pacheco-Molina C; Reyes E; Lima G; Hernandez-Ramirez D; Llorente L; Hernandez-Molina G
    Int J Rheum Dis; 2018 Jun; 21(6):1293-1300. PubMed ID: 29624878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evaluation of disease activity in Sjögren's syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study.
    De Vita S; Gandolfo S; Zandonella Callegher S; Zabotti A; Quartuccio L
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):150-156. PubMed ID: 30156548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of definitive serum biomarkers associated with disease activity in primary Sjögren's syndrome.
    Nishikawa A; Suzuki K; Kassai Y; Gotou Y; Takiguchi M; Miyazaki T; Yoshimoto K; Yasuoka H; Yamaoka K; Morita R; Yoshimura A; Takeuchi T
    Arthritis Res Ther; 2016 May; 18(1):106. PubMed ID: 27180164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.
    Rosas J; Sánchez-Piedra C; Fernández-Castro M; Andreu JL; Martínez-Taboada V; Olivé A;
    Rheumatol Int; 2019 Jun; 39(6):991-999. PubMed ID: 30891620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
    Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
    Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.
    Olsson P; Bodewes ILA; Nilsson AM; Turesson C; Jacobsson LTH; Theander E; Versnel MA; Mandl T
    Rheumatol Int; 2019 Sep; 39(9):1575-1584. PubMed ID: 31139950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
    Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
    Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.
    Liu J; Zhao Z; Zou Y; Zhang M; Zhou Y; Li Y; Pang Z; Jin W
    Clin Rheumatol; 2015 May; 34(5):879-85. PubMed ID: 25564309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proprotein convertase enzyme FURIN is upregulated in primary Sjögren's syndrome.
    Ranta N; Valli A; Grönholm A; Silvennoinen O; Isomäki P; Pesu M; Pertovaara M
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):47-50. PubMed ID: 29465367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial Dysfunction in Primary Sjögren's Syndrome: Correlation with Serum Biomarkers of Disease Activity.
    Caraba A; Iurciuc S; Nicolin M; Iurciuc M
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures.
    Carrillo-Ballesteros FJ; Palafox-Sánchez CA; Franco-Topete RA; Muñoz-Valle JF; Orozco-Barocio G; Martínez-Bonilla GE; Gómez-López CE; Marín-Rosales M; López-Villalobos EF; Luquin S; Castañeda-Chávez A; Oregon-Romero E
    Clin Exp Med; 2020 Nov; 20(4):615-626. PubMed ID: 32506205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
    Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
    Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.
    Brito-Zerón P; Acar-Denizli N; Ng WF; Horváth IF; Rasmussen A; Seror R; Li X; Baldini C; Gottenberg JE; Danda D; Quartuccio L; Priori R; Hernandez-Molina G; Armagan B; Kruize AA; Kwok SK; Kvarnstrom M; Praprotnik S; Sene D; Gerli R; Solans R; Rischmueller M; Mandl T; Suzuki Y; Isenberg D; Valim V; Wiland P; Nordmark G; Fraile G; Bootsma H; Nakamura H; Giacomelli R; Devauchelle-Pensec V; Hofauer B; Bombardieri M; Trevisani VFM; Hammenfors D; Pasoto SG; Retamozo S; Gheita TA; Atzeni F; Morel J; Vollenweider C; Zeher M; Sivils K; Xu B; Bombardieri S; Sandhya P; De Vita S; Minniti A; Sánchez-Guerrero J; Kilic L; van der Heijden E; Park SH; Wahren-Herlenius M; Mariette X; Ramos-Casals M;
    Rheumatology (Oxford); 2020 Sep; 59(9):2350-2359. PubMed ID: 31873754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.